WILMINGTON, MA--(Marketwired - Jul 25, 2013) - Implant Sciences Corporation (
Implant Sciences' QS-B220 desktop explosives and drugs trace detector and QS-H150 handheld explosives trace detector are next-generation technologies built using some of the Company's U.S. patent portfolio, which now consists of 17 patents, with 2 applications pending. These patents cover a broad range of methods including sample collection, analysis, and detection. The Company has recently received patents for hyphenated detection technologies, combining ion mobility spectrometry (IMS), differential mobility spectrometry (DMS), and mass spectroscopy (MS). These new techniques will allow detection of a wider range of threats with significantly lower false alarm rates.
Implant Sciences' Vice President of Technology, Todd Silvestri, stated, "Sampling is one of the core components of fast and accurate trace detection. This invention is an example of Implant Sciences looking beyond traditional trace detection methods to enhance sampling and transport."
"Innovation is key to maintaining and fortifying our technology leadership position in the industry. With each issued patent, we continue to improve upon our technology, furthering our belief that we are the next generation ETD provider. The strength of our intellectual property (IP) portfolio and how we monetize that IP drives our shareholder value," added Dr. Bill McGann, Implant Sciences' Chief Operating Officer.
About the QS-B220 Desktop Explosives and Drugs Trace Detector The QS-B220 uses Ion Mobility Spectrometry (IMS) to rapidly detect and identify trace amounts of a wide variety of military, commercial, and homemade explosives. With significantly lower maintenance requirements than competing systems, the QS-B220 can be deployed for a much lower total cost of ownership than other approved products. Featuring a radioactive material-free design, push-button maintenance and diagnostics, and a patented inCal™ internal automatic calibration system, the QS-B220 brings new levels of performance and convenience to desktop trace detection users with unsurpassed ease of use.
About the QS-H150 Handheld Explosives Trace Detector The QS-H150 utilizes Ion Mobility Spectrometry (IMS) technology, providing fast, accurate detection of trace amounts of a wide variety of military, commercial, and homemade explosives. Built with no radioactive materials and featuring a low-maintenance, self-calibrating, and self-clearing design, the QS-H150 provides very high levels of operational availability. The QS-H150 has been proven to perform well in a wide variety of temperatures and challenging environments, from humid jungles to dry, sand swept deserts.
About Implant Sciences Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to currently have product approval from the Transportation Security Administration. Implant Sciences has developed proprietary technologies used in its commercial explosives and drugs trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com .
Safe Harbor Statement This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; that our success depends on our ability to obtain new patents and operate without infringing on the proprietary rights of others; that we may not obtain the patents we have applied for; that the validity and breadth of claims in technology patents involve complex legal and factual questions and, therefore, may be highly uncertain; that any patents we may obtain may be may be challenged and subsequently invalidated, that we may incur substantial costs in asserting our patent rights; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.
Contact: Implant Sciences Corporation Company Contact: Glenn Bolduc CEO 978-752-1700 Email Contact or Investor Contact: Laurel Moody 646-810-0608 Email Contact
